Cannabics Bolsters Team to Develop Cannabinoid Treatments for Cancer
Cannabics Pharmaceuticals has announced the appointment of Haleli Sharir, Ph.D. as principal scientist and Nir Kfir, Ph.D. as senior scientist. The two new team members will support Cannabics' data-discovery process with the goal of identifying new cannabinoid diagnostic tests and treatments for cancer.
Dr. Sharir is widely recognized for her role in identifying a potentially new cannabinoid receptor, GPR55. She was a member of a research group responsible for discovering that human GPR55 is activated by several types of cannabinoids. Dr. Sharir has published nine peer-reviewed research papers on the topic. The research was funded by the National Institute of Health (NIH/NIDA), and results are available through the National Center for Biotechnology Information (NCBI).
Dr. Sharir is also proficient in the development, optimization and implementation of high-throughput screening (HTS) and high-content screening (HCS) assessments – approaches to cell biology that are used for large-scale applications.
Dr. Kfir has a background in molecular genetics and specializes in RNA processing and chromatin organization. His previous work has focused on HTS and on researching new chemotherapy treatments that restore a cancer cell's ability to undergo "programmed cell death".
"Dr. Sharir and Dr. Kfir's experience will effectively guide Cannabics' data discovery process and will streamline our compound screenings," said Cannabics Pharmaceuticals Co-Founder and CEO Eyal Barad. "The combined expertise of these leading scientists will help us develop and implement HCS analysis to address the effects of cannabinoids on cancer growth."
